MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
about
New Insights into the Crossroads between EMT and Stemness in the Context of CancerRole of microRNAs in chemoresistanceThe dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker valueMicroRNAs and Growth Factors: An Alliance Propelling Tumor ProgressionThe crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticityHsa-miR-19a is associated with lymph metastasis and mediates the TNF-α induced epithelial-to-mesenchymal transition in colorectal cancerRe-expression of miR-200c suppresses proliferation, colony formation and in vivo tumor growth of murine claudin-low mammary tumor cells.Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epitheliumYes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Knockdown of lncRNA-ATB suppresses autocrine secretion of TGF-β2 by targeting ZNF217 via miR-200c in keloid fibroblasts.MicroRNA-200b acts as a tumor suppressor in osteosarcoma via targeting ZEB1miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomesA miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.miR-340 and ZEB1 negative feedback loop regulates TGF-β- mediated breast cancer progressionDownregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer.Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancerGenomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomasElevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress.E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer CellsThe role of microRNAs in human breast cancer progression.microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer.The Role of MicroRNAs in the Chemoresistance of Breast Cancer.MicroRNAs and Cancer Drug Resistance.Long non-coding RNA ATB promotes growth and epithelial-mesenchymal transition and predicts poor prognosis in human prostate carcinoma.Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis.The role of TGF-β and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma.Glabridin inhibits cancer stem cell-like properties of human breast cancer cells: An epigenetic regulation of miR-148a/SMAd2 signaling.Noncoding RNAs in Therapeutic Resistance of Cancer.Approaches for targeting cancer stem cells drug resistance.Involvement of microRNAs in HER2 signaling and trastuzumab treatment.MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis.Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells.Impact of non-neoplastic vs intratumoural hepatitis B viral DNA and replication on hepatocellular carcinoma recurrenceThe Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas.
P2860
Q26764831-BFACABC4-1BCA-4CCC-95BF-8850C6297EBCQ26770485-8AC2C255-DE76-41FF-8473-F5C484893A7AQ26782620-CBAF2381-2E8F-4152-A484-1D6FB36809BDQ26796592-B6ED11DE-C20D-4253-B131-B1FF343A7CA8Q28070337-18D6177C-1EB7-4D81-8472-750541EF8225Q33552969-ABCD8B69-A7FC-4169-A3FA-0AEEB0D36DBEQ33618841-E62C92A5-5F28-4CC2-B3B2-AE5860C9EC36Q35176428-F1FC0D1C-279E-4161-9DCA-5AE93C003BCBQ35550226-E4EEB78D-5854-44D2-B49A-5AC66CEDA316Q35793883-6AE26D70-B008-48B9-AF2D-371FE729CBE4Q36089079-57EFB016-04D1-4EF8-9822-7F8DEBE8F306Q36269777-10FBFFA2-957C-4D99-9D1F-7383B590118CQ36544839-9A39E14D-C941-463B-B456-058A0763035EQ36810185-CDC112DF-BB9E-47A7-A219-8AD5B3EF4AFCQ36955656-4004A7F4-AC1B-480B-BB2C-82FC52B11F9BQ36962950-456AF7CF-900E-4FE6-9935-41E5A3F75913Q37077423-EAEA57C5-CF22-42D9-8D1B-2BCC7628293AQ37174919-EA162605-539B-4712-9DB7-33E02D18B1D0Q37271711-9E23137B-B373-443A-9887-F4C0905B2EF4Q37295569-4D266D0F-C1AF-4621-A8EF-3C8A484668F5Q37354017-9C879B87-898A-4AE8-9591-0ED146A82BBBQ37588298-AB3474DC-67C5-4CF7-BBD5-F4DACED2360DQ37688154-739C400F-6FF4-4AA0-BEDA-79549D4EC903Q37709040-27437AE1-0F1F-4ED2-8941-BAC22C88738EQ37716100-E36C9A81-B0AC-47D5-8A71-CA85052DBF2BQ38221040-B1FC77DE-DF24-46A6-A65C-D59197A1648BQ38336073-E7E59C0D-41B0-416A-AAF5-6905293005C9Q38574546-118D64BE-867E-434C-8D0F-44F725C1E1C4Q38748118-FC54F6EC-E314-444F-8EAB-0067386A1E89Q38771232-DA72F885-AF7E-440B-916D-8D5CDB20B2F1Q38772722-C1C6AE02-112E-4DAD-84AA-A8AC16FFB8B7Q38788923-A7B23C77-12DB-4DEB-8386-2D443A19E17AQ38874118-637D6D5A-F1FC-4E97-8455-7370AAD1ABE8Q38885495-43B3A889-3035-473A-8D42-6EB2FE466E55Q38971795-6B32732B-9F07-4C6A-B140-97D5D9AC9DA2Q38979308-480E795A-AA41-4798-BC56-A28946331629Q39145491-06B967A4-D4AB-4356-B0F3-C77AD254995FQ39254523-495A44BC-71BC-4666-9819-02457ACE92A3Q40616989-2A095866-647D-46FB-8D53-6107C4A69D84Q42516196-15D0A55D-F427-4DF0-976D-FB9AE55905F2
P2860
MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
MiR-200c suppresses TGF-β sign ...... 217 and ZEB1 in breast cancer.
@en
MiR-200c suppresses TGF-β sign ...... 217 and ZEB1 in breast cancer.
@nl
type
label
MiR-200c suppresses TGF-β sign ...... 217 and ZEB1 in breast cancer.
@en
MiR-200c suppresses TGF-β sign ...... 217 and ZEB1 in breast cancer.
@nl
prefLabel
MiR-200c suppresses TGF-β sign ...... 217 and ZEB1 in breast cancer.
@en
MiR-200c suppresses TGF-β sign ...... 217 and ZEB1 in breast cancer.
@nl
P2093
P2860
P356
P1476
MiR-200c suppresses TGF-β sign ...... 217 and ZEB1 in breast cancer.
@en
P2093
An-Gang Yang
Guo-Xu Zheng
Hua-Yu Zhu
Meng-Yao Zhang
Wen-Dong Bai
Wen-Jin Xi
Xing-Ming Ye
P2860
P304
P356
10.1002/IJC.28782
P50
P577
2014-03-03T00:00:00Z